> Altea Therapeutics raised more than $30 million in venture capital for development of pain management and diabetes patches. The Series C financing was led by Aperture Venture Partners, but includes Altea's Series B investors Domain, Venrock, and vSpring Capital. Release
> Par Pharmaceutical loses Zofran patent fight with GlaxoSmithKline. Release
> Ranbaxy's JV with Japan's Nippon Chemiphar unveils maiden diabetes drug. Story
> Human tissue supplier CryoLife agrees to pay $23 million to settle lawsuit over contamination. Report
> Biolex Therapeutics acquires LemnaGene, a French biotech startup researching protein development. Release
> Boehringer Ingelheim wins regulatory nod for tipranavir, a non-peptidic protease inhibitor. Release
> Cortex launches Phase IIa studies of Ampakine CX717 for ADHD and Alzheimer's Disease. Release
> Savient to set Phase III parameters with FDA on gout drug. Story
> British vaccine firm Acambis is starting trials of a vaccine to prevent infections from a new strain of clostridium difficile that has spawned outbreaks in at least 15 U.K. hospitals. Report
and finally...Sorry, herbal enthusiasts, researchers says Echinacea is a dud against colds. Article